Med. Pro Praxi 2004; 1: 31-32

Chyby a úskalí terapie statiny

MUDr. Lubor Goláň1,2
1 II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha
2 II. interní klinika, VFN, Praha

Keywords: kardiovaskulární mortalita, statiny, nežádoucí účinky, hepatopatie, myopatie, rhabdomyolýza.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Goláň L. Chyby a úskalí terapie statiny. Med. praxi. 2004;2(1):31-32.

Statiny patří mezi nejpoužívanější léky v kardiologii. Jejich význam spočívá nejen ve snížení cholesterolu, a tím ve zlepšení rizikového profilu nemocných, ale především ve snížení mortality na kardiovaskulární nemoci u pacientů v sekundární i primární prevenci. S rostoucím používáním statinů však roste riziko nežádoucích účinků. Mezi nejzávažnější nežádoucí účinky patří rhabdomyolýza. Musíme si být rovněž vědomi možnosti lékových interakcí, především s léky metabolizovanými cytochromem cyp3A4.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Davidson MH. Controversy surrounding the safety of cerivastatin. Expert Opin Drug Saf. 2002; 1: 207-212. Go to original source... Go to PubMed...
    2. Evans M, Rees A. The myotoxicity of statins. Curr Opin Lipidol. 2002; 13: 415-420. Go to original source... Go to PubMed...
    3. Gotto AM Jr. Risks and benefits of continued aggressive statin therapy. Clin Cardiol. 2003; 26: III3-12. Go to original source... Go to PubMed...
    4. Iglesias P, Diez JJ. New drugs for the treatment of hypercholesterolaemia. Expert Opin Investig Drugs. 2003; 12: 1777-1789. Go to original source... Go to PubMed...
    5. Moghadasian MH. A safety look at currently available statins. Expert Opin Drug Saf. 2002; 1: 269-274. Go to original source... Go to PubMed...
    6. Sica DA, Gehr TW. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient. Curr Opin Nephrol Hypertens. 2002; 11: 123-133. Go to original source... Go to PubMed...
    7. Škulec R, Linhart A, Hnátek T, et al. Dlouhodobá léčba statiny u pacientů s ischemickou chorobou srdeční po koronární angioplastice. Vnitř. Lék. 2003; 49: 285-290.
    8. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002; 41: 343-370. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.